Back to results
US 12,215,131 B2Granted
IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to IL2 agonists with improved therapeutic profiles.
Claims25
A fusion protein comprising a polypeptide chain which comprises, in an N- to C-terminal orientation:
- (a) a variant IgG1 Fc domain or a variant IgG4 Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and/or reduce effector function;
- and
- (b) an IL2 moiety comprising, in an N- to C-terminal orientation:
- (i) an IL2-Rα domain comprising the amino acid sequence of SEQ ID NO:4;
- and
- (ii) an IL2 domain comprising the amino acid sequence of SEQ ID NO:2.
3 more elements
Dependencies are inferred from the claim text.